A top cancer R&D exec at Genentech joins the exodus, jumping to a marquee China biotech as the new oncology chief, dealmaker
In the oncology world, there’s no better hunting ground for cancer R&D execs than Genentech. The biotech franchise at Roche has worked on some of the leading drugs in the field, proven themselves with blockbuster returns, and carries weight for whatever it says and does.
The exodus of R&D talent out of the South San Francisco hub is a testament to their success.
Now one of their top research execs has been raided by a top China biotech player to satisfy not just their need for an oncology R&D chief as they build up their muscle in discovery and drug development, but also add a spotter for new cancer drug deals.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.